Сообщений в теме: 1942

[Alexey877]

у Вас улучшения давал?

[djtim]

у Вас улучшения давал?

У меня он давал побочки, не смог зайти на норм дозу

[Alexey877]

если честно я бы Вам посоветовал бринтеликс за место аминокислоты, тк антидепресанта у Вас нет
Мой лечащий прямо уперто хочет что бы я его пропил, но пиразидол нужно отменить и ждать 2 недели отмены и только потом начинать пить, я пока себе не могу так позволить

[djtim]

если честно я бы Вам посоветовал бринтеликс за место аминокислоты, тк антидепресанта у Вас нет
Мой лечащий прямо уперто хочет что бы я его пропил, но пиразидол нужно отменить и ждать 2 недели отмены и только потом начинать пить, я пока себе не могу так позволить

Он у меня на заметке. Депрессии сейчас нет, поэтому антидепрессант не особенно нужен. Но для усиления действия НЛ вполне может подойти

[Valerianka]

а как вы считаете понятие улучшения чисто в человеческом понимании а не в психиатрическом?

[NMDA]

Агонисты mGluR и GRI не прошли РКИ. 

[djtim]

Аурорикс для негативной симптоматики

The effect of augmentation with moclobemide on symptoms of schizophrenia.
https://www.ncbi.nlm...pubmed/10435775

[NMDA]

Окситоцин и концепции шизофренической "мать-холодильник". 

 

A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia.

 

Social cognition is impaired in people with schizophrenia and these deficits are strongly correlated with social functioning. Oxytocin is a hypothalamic peptide that contributes to maternal infant bonding and has diverse pro-social effects in adults. This study tested the hypothesis that 12weeks of intranasal oxytocin will improve social cognitive function in outpatients with schizophrenia and schizoaffective disorder. Sixty-eight eligible participants were randomized to oxytocin (24IU twice daily) or placebo. Social cognitive function was assessed using the Emotion Recognition-40, Brüne Theory of Mind, Reading the Mind in the Eyes test, Trustworthiness task and Ambiguous Intentions Hostility Questionnaire at baseline, 6weeks and 12weeks. In addition, social function was assessed using the Specific Levels of Functioning Scale and a role-play test, and psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Fifty-five participants completed the 12-week trial. The study found no evidence for a differential advantage of oxytocin over placebo on social cognition. Among secondary outcomes, there was a modest advantage for oxytocin over placebo on a component of social functioning, although there was also evidence that the placebo group outperformed the oxytocin group on the role-play task. No between-group differences emerged on measures of psychopathology in pre-specified comparisons, but oxytocin showed significant within-group reduction in PANSS negative symptoms and significant between-group improvement in negative symptoms in the schizophrenia subgroup. Further testing is needed to clarify whether oxytocin has therapeutic potential for social cognitive deficits and/or negative symptoms in people with schizophrenia.

 

https://www.ncbi.nlm...pubmed/28094169

[NMDA]

Мета-анализ РКИ на 206 пациентах с шизофренией окситоцин vs плацебо. Окситоцин превзошел плацебо по шкале оценки негативных симптомов. 

 

Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.

 

The aim of this study was to perform a systematic review and an updated and comprehensive meta-analysis of oxytocin augmentation therapy in patients with schizophrenia who received antipsychotic agents. Data published up to 07/11/2015 were obtained from PubMed, PsycINFO, and Cochrane Library databases. We conducted a systematic review and meta-analysis of patients' data from randomized controlled trials (RCTs) comparing oxytocin with placebo. Relative risk (RR), standardized mean difference (SMD), and 95 % confidence intervals (95 % CI) based on the random-effects model were calculated. We included seven RCTs; the total sample size was 206 patients. Oxytocin was superior to placebo for decreasing the Positive and Negative Syndrome Scale (PANSS) general subscale scores (SMD = -0.44, 95 % CI -0.82 to -0.06, p = 0.02, I (2) = 0 %, N = 4, n = 112); however, it was not different from placebo for total symptoms (SMD = -0.46, 95 % CI -1.20 to 0.28, p = 0.22, I (2) = 80 %, N = 6, n = 162), positive symptoms (SMD = -0.18, 95 % CI -0.87 to 0.51, p = 0.60, I (2) = 81 %, N = 6, n = 192), and negative symptoms (SMD = -0.34, 95 % CI -0.76 to 0.08, p = 0.12, I (2) = 55 %, N = 7, n = 214). However, a sensitivity analysis including only oxytocin administration on consecutive days studies was superior to placebo in negative symptoms (SMD = -0.44, 95 % CI -0.87 to -0.01, p = 0.04, I (2) = 51 %, N = 6 n = 192). There were no significant differences for all-cause discontinuation (RR = 1.02) and individual side effects such as headache and dizziness between oxytocin and placebo. Oxytocin may improve PANSS general subscale scores in schizophrenia and seems to be well tolerated. However, because the number of studies in the current analysis was small, further study will be required using larger sample sizes.

 

https://www.ncbi.nlm...pubmed/26303414

[djtim]

Флуоксетин значительно усиливает действие атипика.

https://www.ncbi.nlm.../pubmed/7868850


Итого, судя по представленной информации, основные АД которые эффективны:

Эсциталопрам, флуоксетин, миртазапин, бупропион, иксел.
Дорогие и недоступные в аптеках РФ- аурорикс, селегилин, разагилин.